(Sharecast News) - Pharmaceutlcal firms Moderna and MSD (Merck Sharp & Dohme (UK) Limited) said on on Wednesday that a personalised mRNA melanoma vaccine they are jointly developing had shown positive results in a first-ever late-stage trial.
The companies hailed positive topline results from the Phase 3 trial of intismeran, a...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE